The goal is to to bring more affordable,high-quality biologic medicines to patients.
Our leading pipeline is a next generation of anti-IgE antibody (LP-003), which is already in Phase III stage, and prepare for BLA in 2026. The other pipeline is a bifunctional complement inhibitor (LP-005) , which is in Phase II at present.
Dr. Sun, is one of the serial successful entrepreneurs in the
biopharmaceutical industry with proven track records of successful biopharmaceutical
development in both China and the United States. Dr. Sun was a shareholder of Tanox Inc., a
biotech company established in Texas, the United States in 1986 and listed on the NASDAQ
Stock Market in 2000. He co-founded PharMab Inc. in 2001 and our Company in 2020. Dr. Sun
obtained a Ph.D. in cell biology from the Iowa State University in the United States and has
over 55 years of experience in biomedical research and development. He has published more
than 30 research papers in leading chemistry and medicinal chemistry journals and has been
granted 30 patents, including 16 registered in the United States and 12 patents registered in the
PRC. He was the main inventor behind the groundbreaking first-generation anti-IgE antibody,
omalizumab (marketed as Xolair®), which emerged as a blockbuster in asthma and allergic
diseases, and F-627/long-acting G-CSF (marketed as Benegrastim, Ryzneuta®). Dr. Sun’s
industry insights and vision are crucial to our continuous innovation.
Dr. Liu, our co-founder, has over 15 years of experience in research and
development and commercialization of biopharmaceutical drugs. Dr. Liu played a pivotal role
in both domestic and international programs of development of several innovative drugs.
Notably, Dr. Liu was deeply involved in the development of a long-acting G-CSF (marketed
as Ryzneuta®), which successfully completed phase III clinical trials globally and received
market approval from the Food and Drug Administration in the United States and the NMPA.